已收盘 08-16 16:00:00 美东时间
0.000
0.00%
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas, May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliate...
05-09 02:10
原标题:巨头们的新战场:豪赌炎症性肠病 在许多人的认知中,胃肠不适只是一件小事,吃点药、休息休息便会好转。但对于重度克罗恩病患者而言,这却是一场持续不断、难以...
04-01 14:45
(来源:医曜) 在许多人的认知中,胃肠不适只是一件小事,吃点药、休息休息便会好转。但对于重度克罗恩病患者而言,这却是一场持续不断、难以摆脱的噩梦:他们常常被剧烈...
03-31 07:28
New appointees reinforce the Company's momentum in building a leading oncology therapeutics company Lead asset CR-001, a tetravalent PD-1 x VEGF bispecific antibody, on track for IND filing ...
02-25 05:30
礼来的管线布局集中,主要聚焦在代谢、神经系统、肿瘤和自身免疫领域。在备受关注的代谢领域外,近年来,礼来在自身免疫疾病领域也取得了高速的发展,2019-2023年...
2024-11-05 07:30
2024 Financial GuidanceThe company updated 2024 full-year revenue guidance to between $45.4 billion and $46.0 billion. The company is investing heavily in increasing the supply of tirzepatide and has been balancing
2024-10-30 18:48
Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative colitis and Crohn's disease patients.
2024-10-29 00:05
礼来公司宣布成功完成对Morphic Holding, Inc. 的收购。Morphic是一家生物制药公司,开发用于治疗严重慢性疾病的口服整合素疗法,包括用于治...
2024-08-19 14:54
The latest announcement is out from Morphic Holding (MORF). Amidst a significan...
2024-08-17 04:31
Morphic Holding: On August 16, 2024, Company Terminated the Company’s 2018 Stoc...
2024-08-17 04:15